NVS vs VRTX
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | NVS | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $156.11 | $477.10 | |
| Market cap as of 2026-08-03 | $232.1B | $121.1B | |
| P/E as of 2026-08-03 | 22.53 | 28.29 | NVS lower |
| PEG as of 2026-08-03 | 3.66 | 2.28 | VRTX lower |
| Net margin as of 2026-08-03 | +22.5% | +35.5% | VRTX higher |
| Gross margin as of 2026-08-03 | +75.0% | +86.2% | VRTX higher |
| Operating margin as of 2026-08-03 | +29.9% | +38.3% | VRTX higher |
| ROE as of 2026-08-03 | +29.9% | +23.9% | NVS higher |
| ROA as of 2026-08-03 | +11.1% | +17.2% | VRTX higher |
| Debt / equity as of 2026-08-03 | 1.18 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.3% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Dividend yield as of 2026-08-03 | +2.9% | n/a | |
| Beta as of 2026-08-03 | 1.17 | 0.48 | |
| 1-year return as of 2026-07-27 close | +32.6% | +4.4% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.